RTB101

Restorbio Inc. · Phase 2 active Small molecule

At a glance

Generic name	RTB101
Also known as	Dactolisib, BEZ235
Sponsor	Restorbio Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly (PHASE3)
Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes (PHASE2)
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults (PHASE2)
Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RTB101 CI brief — competitive landscape report
RTB101 updates RSS · CI watch RSS
Restorbio Inc. portfolio CI